These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2142738)

  • 21. Use of the disutility ratio in prenatal screening for Down's syndrome.
    van der Meulen JH; Mol BW; Pajkrt E; van Lith JM; Voorn W
    Br J Obstet Gynaecol; 1999 Feb; 106(2):108-15. PubMed ID: 10426675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biparietal diameter and crown-rump length in fetuses with Down's syndrome: implications for antenatal serum screening for Down's syndrome.
    Wald NJ; Smith D; Kennard A; Palomaki GE; Salonen R; Holzgreve W; Pejtsik B; Coombes EJ; Mancini G; MacRae AR
    Br J Obstet Gynaecol; 1993 May; 100(5):430-5. PubMed ID: 8518242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second trimester screening for Down's syndrome: 7 years experience.
    Beaman JM; Goldie DJ
    J Med Screen; 2001; 8(3):128-31. PubMed ID: 11678551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening of maternal serum for fetal Down's syndrome in the first trimester.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
    N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for Down's syndrome using an iso-risk curve based on maternal age and serum alpha-fetoprotein level.
    Tabor A; Larsen SO; Nielsen J; Nielsen J; Philip J; Pilgaard B; Videbech P; Nørgaard-Pedersen B
    Br J Obstet Gynaecol; 1987 Jul; 94(7):636-42. PubMed ID: 2441737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
    Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
    J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fetuses with Down's Syndrome detected by prenatal screening are more likely to abort spontaneously than fetuses with Down's Syndrome not detected by prenatal screening.
    Leporrier N; Herrou M; Morello R; Leymarie P
    BJOG; 2003 Jan; 110(1):18-21. PubMed ID: 12504930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective audit of different antenatal screening policies for Down's syndrome in eight district general hospitals in one health region.
    Wellesley D; Boyle T; Barber J; Howe DT
    BMJ; 2002 Jul; 325(7354):15. PubMed ID: 12098722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome.
    Wald NJ; Cuckle HS; Densem JW; Nanchahal K; Canick JA; Haddow JE; Knight GJ; Palomaki GE
    Br J Obstet Gynaecol; 1988 Apr; 95(4):334-41. PubMed ID: 2454652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A sonographic sign for the detection in the second trimester of the fetus with Down's syndrome.
    Benacerraf BR; Barss VA; Laboda LA
    Am J Obstet Gynecol; 1985 Apr; 151(8):1078-9. PubMed ID: 3157321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gestational age standardized nuchal thickness values for estimating mid-trimester Down's syndrome risk.
    Bahado-Singh RO; Oz UA; Kovanci E; Deren O; Feather M; Hsu CD; Copel JA; Mahoney MJ
    J Matern Fetal Med; 1999; 8(2):37-43. PubMed ID: 10090488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humerus and femur length shortening in the detection of Down's syndrome.
    Nyberg DA; Resta RG; Luthy DA; Hickok DE; Williams MA
    Am J Obstet Gynecol; 1993 Feb; 168(2):534-8. PubMed ID: 8438923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.
    Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2007 Oct; 90(10):1970-6. PubMed ID: 18041410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study.
    Rozenberg P; Malagrida L; Cuckle H; Durand-Zaleski I; Nisand I; Audibert F; Benattar C; Tribalat S; Cartron M; Lemarié P; Stoessel J; Capolagui P; Jansé-Marec J; Barbier D; Allouch C; Perdu M; Roberto A; Lahna Z; Giudicelli Y; Ville Y
    Hum Reprod; 2002 Apr; 17(4):1093-8. PubMed ID: 11925411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does gender have an impact on the sonographic detection of second-trimester fetuses with Down's syndrome?
    Benacerraf BR; Miller WA; Nadel A; Pauker S; Bromley B
    Ultrasound Obstet Gynecol; 1995 Jan; 5(1):30-3. PubMed ID: 7850586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
    Wald NJ; Watt HC; Hackshaw AK
    N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fifth digit measurement in normal pregnancies: a potential sonographic sign of Down's syndrome.
    Goldstein I; Gomez K; Copel JA
    Ultrasound Obstet Gynecol; 1995 Jan; 5(1):34-7. PubMed ID: 7850587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urine free beta hCG and beta core in pregnancies affected by Down's syndrome.
    Spencer K; Aitken DA; Macri JN; Buchanan PD
    Prenat Diagn; 1996 Jul; 16(7):605-13. PubMed ID: 8843469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-trimester Down's syndrome screening by fetal nuchal translucency measurement in Taiwan.
    Jou HJ; Shih JC; Wu SC; Li TC; Tzeng CY; Hsieh FJ
    J Formos Med Assoc; 2001 Apr; 100(4):257-61. PubMed ID: 11393125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.